Ticker

Profusa ($PFSA) shares down 40% to $1.10. Company signs LOI for $30M acquisition to scale its diagnostics and monitoring business.

Company secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applications BERKELEY, CA, April 06, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the…

Applied Optoelectronics Inc (NASDAQ: AAOI) rose in pre-market trading after securing an 800G transceiver order worth $71 million, bringing total orders from a major customer to $124 million. Other gainers include Xiao-I Corp (NASDAQ: AIXI), Profusa Inc (NASDAQ: PFSA), and Soleno Therapeutics Inc (NASDAQ: SLNO). Losers include Intercont (Cayman) Ltd (NASDAQ: NCT), Visionary Holdings Inc (NASDAQ: GV), and PMGC…

Medline (NASDAQ: MDLN - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk. Profitability This table compares Medline and Profusa's net margins, return

After Reevaluating its Near-term Capital Needs Given the Recent Changes in its Projected 2026 Revenue and Mayo Collaboration, the Company Determined that a $15 Million Offering is Not Required to Achieve Near-term Revenue Projections